Melatonin potentiates the antineoplastic effects of venetoclax in acute myeloid leukemia cells

Melatonin and cancer: towards a time-sensitive oncological adjunct

10.1016/j.clinsp.2025.100834 · doi-reference

Adjuvant chemotherapy with melatonin for targeting human cancers: a review

10.1002/jcp.27259 · doi-reference

Molecular mechanisms of the pro-apoptotic actions of melatonin in cancer: a review

10.1517/14728222.2013.834890 · doi-reference

Melatonin combined with antineoplastic drugs or natural products for cancer treatment: an update

10.1016/j.crphar.2025.100239 · doi-reference

Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia

10.1038/s41392-021-00870-3 · doi-reference

Metabolic reprogramming represents a targetable mechanism to overcome acquired resistance to venetoclax in acute myeloid leukemia

10.1016/j.bbadis.2025.168065 · doi-reference

[Melatonin enhances the effect of ABT-737 in acute monocytic leukemia THP-1 cells]

10.1134/s002689332401014x · doi-reference

Melatonin inhibits MLL-rearranged leukemia via RBFOX3/hTERT and NF-kappaB/COX-2 signaling pathways

10.1016/j.canlet.2018.11.037 · doi-reference

Inhibition of proliferation and induction of apoptosis by melatonin in human myeloid HL-60 cells

10.1111/j.1600-079x.2006.00392.x · doi-reference

Promising antineoplastic actions of melatonin

10.3389/fphar.2018.01086 · doi-reference

Melatonin as a regulator of apoptosis in leukaemia: molecular mechanism and therapeutic perspectives

10.3389/fphar.2023.1224151 · doi-reference

Venetoclax-based combinations in acute myeloid leukemia: current evidence and future directions

10.3389/fonc.2020.562558 · doi-reference

The spectrum of venetoclax-based treatments in acute myeloid leukemia

10.3390/cancers18081201 · doi-reference

Targeting acute myeloid leukemia with venetoclax; biomarkers for sensitivity and rationale for venetoclax-based combination therapies

10.3390/cancers14143456 · doi-reference